1219220-82-2 Usage
Description
Tert-butyl 2-carbamoylazetidine-1-carboxylate is a chemical compound characterized by its molecular formula C9H16N2O3. It is a derivative of azetidine, featuring a four-membered ring composed of nitrogen and carbon atoms. tert-butyl 2-carbamoylazetidine-1-carboxylate is widely recognized for its versatility in organic synthesis and pharmaceutical research, attributed to its capacity to form diverse chemical bonds and functional groups. Its unique chemical structure and properties render it a valuable tool for the creation of new drugs and other biologically active molecules.
Uses
Used in Pharmaceutical Research and Development:
Tert-butyl 2-carbamoylazetidine-1-carboxylate is utilized as a key building block in the synthesis of pharmaceuticals. Its ability to form various chemical bonds and functional groups allows for the development of innovative drug candidates with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, tert-butyl 2-carbamoylazetidine-1-carboxylate is employed as a precursor in the synthesis of new agrochemicals. Its unique properties contribute to the creation of novel compounds with potential applications in crop protection and pest control.
Used in Organic Synthesis:
As a versatile intermediate in organic synthesis, tert-butyl 2-carbamoylazetidine-1-carboxylate is used to construct complex organic molecules. Its reactivity and capacity to form different functional groups make it an indispensable component in the synthesis of a wide range of organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1219220-82-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,1,9,2,2 and 0 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1219220-82:
(9*1)+(8*2)+(7*1)+(6*9)+(5*2)+(4*2)+(3*0)+(2*8)+(1*2)=122
122 % 10 = 2
So 1219220-82-2 is a valid CAS Registry Number.
1219220-82-2Relevant articles and documents
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders
Noji, Satoru,Hara, Yoshinori,Miura, Tomoya,Yamanaka, Hiroshi,Maeda, Katsuya,Hori, Akimi,Yamamoto, Hiroshi,Obika, Shingo,Inoue, Masafumi,Hase, Yasunori,Orita, Takuya,Doi, Satoki,Adachi, Tsuyoshi,Tanimoto, Atsuo,Oki, Chika,Kimoto, Yukari,Ogawa, Yoshihiro,Negoro, Tamotsu,Hashimoto, Hiromasa,Shiozaki, Makoto
, p. 7163 - 7185 (2020/09/11)
Dermatologic disorders such as atopic dermatitis arise from genetic and environmental causes and are complex and multifactorial in nature. Among possible risk factors, aberrant immunological reactions are one of the leading etiologies. Immunosuppressive agents including topical steroids are common treatments for these disorders. Despite their reliability in clinical settings, topical steroids display side effects, typified by skin thinning. Accordingly, there is a need for alternate effective and well-tolerated therapies. As part of our efforts to investigate new immunomodulators, we have developed a series of JAK inhibitors, which incorporate novel three-dimensional spiro motifs and unexpectedly possess both excellent physicochemical properties and antidermatitis efficacy in the animal models. One of these compounds, JTE-052 (ent-60), also known as delgocitinib, has been shown to be effective and well-tolerated in human clinical trials and has recently been approved in Japan for the treatment of atopic dermatitis as the first drug among Janus kinase inhibitors.
